Literature DB >> 11283964

Sensitivity to naloxone of the behavioral signs of morphine withdrawal and c-Fos expression in the rat CNS: a quantitative dose-response analysis.

S Le Guen1, C Gestreau, J M Besson.   

Abstract

Several studies have used c-Fos expression to delineate the neural substrate underlying naloxone-precipitated morphine withdrawal (MW). However, because behavioral manifestations of MW depend on both the degree of dependence and the doses of naloxone (NAL), a comprehensive study would require examining c-Fos expression in relation with the degree of MW. Here, changes in behavior and in c-Fos-like immunoreactivity (FLI) were studied in the same rats after injection of three doses of NAL to precipitate various degrees of MW. Fifteen established signs of MW were examined for 1 hour after NAL injection, and FLI was quantified in 52 regions of the brain and in the lumbosacral spinal cord. Linear regression analyses were used to examine changes in numbers of signs and FLI neurons with the doses of NAL, and data were considered dose-related for a statistical level of significance of P < 0.05. In summary, autonomic signs of MW increased in a dose-related manner, whereas somatomotor signs did not. After MW, 33 central nervous system regions exhibited significant increases in FLI and were, thus, considered as important neural correlates of MW. Twenty of them displayed dose-related increases in c-Fos expression and correspond to regions related to autonomic functions. Low c-Fos expression was detected in some regions involved in motor control or in reward, suggesting either their minor role in MW or a limitation of the technique. This dose-response analysis suggests that the increase in the severity of autonomic manifestations of MW is associated with a gradual activation of major structures of the autonomic nervous system. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283964     DOI: 10.1002/cne.1140

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  6 in total

1.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

2.  Differential respiratory control of the upper airway and diaphragm muscles induced by 5-HT1A receptor ligands.

Authors:  Stephane Besnard; Hanan Khemiri; Fabienne Masse; Pierre Denise; Marion Verdaguer; Christian Gestreau
Journal:  Sleep Breath       Date:  2011-01-09       Impact factor: 2.816

3.  Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity.

Authors:  Agnieszka Gieryk; Barbara Ziolkowska; Wojciech Solecki; Jakub Kubik; Ryszard Przewlocki
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

4.  Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of naloxone-precipitated opioid withdrawal.

Authors:  Tuan Trang; Maaja Sutak; Remi Quirion; Khem Jhamandas
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

5.  Withdrawal-induced c-Fos expression in the rat centromedial amygdala 24 h following a single morphine exposure.

Authors:  Chunyu Jin; Hiroaki Araki; Mari Nagata; Katsuya Suemaru; Kazuhiko Shibata; Hiromu Kawasaki; Takashi Hamamura; Yutaka Gomita
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

6.  Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone.

Authors:  Ebony M Glover; Michael Davis
Journal:  Psychopharmacology (Berl)       Date:  2008-03-07       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.